Leave Your Message

Groundbreaking Results of CD7-Targeted CAR-T Therapy for T-ALL and T-LBL


A recent clinical trial has demonstrated significant advances in the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) using CD7-targeted chimeric antigen receptor (CAR) T cell therapy. The study, conducted by a team from Hebei Yanda Lu Daopei Hospital and Lu Daopei Institute of Hematology, involved 60 patients who received a single dose of naturally selected anti-CD7 CAR (NS7CAR) T cells.

The trial results are highly encouraging. By day 28, 94.4% of patients achieved deep complete remission (CR) in bone marrow. Additionally, among the 32 patients with extramedullary disease, 78.1% showed a positive response, with 56.3% achieving complete remission and 21.9% achieving partial remission. The two-year overall survival and progression-free survival rates were 63.5% and 53.7%, respectively.

CAR-T Study.png

This innovative therapy is noteworthy for its manageable safety profile, with cytokine release syndrome occurring in 91.7% of patients (mostly grade 1/2), and neurotoxicity observed in 5% of cases. Furthermore, the study found that patients who proceeded with consolidation transplants after achieving CR had significantly higher progression-free survival rates compared to those who did not.

Our company is also exploring the potential of CD7 CAR-T cell therapy with our proprietary product, aiming to contribute to the advancement of treatments for T-cell malignancies.

These findings underscore the potential of CD7-targeted CAR-T cell therapy to offer new hope for patients with refractory or relapsed T-ALL and T-LBL, marking a significant milestone in the ongoing battle against these challenging diseases.